TRAVERE THERAPEUTICS, INC. Deferred Tax Assets, Charitable Contribution Carryforwards
TRAVERE THERAPEUTICS, INC. (TVTX) had Deferred Tax Assets, Charitable Contribution Carryforwards of $5.70 million as of 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross
us-gaap:DeferredTaxAssetsCharitableContributionCarryforwards · last filed 2026-02-19
- 2025-12-31: Deferred Tax Assets, Charitable Contribution Carryforwards $5.70M.
- 2024-12-31: Deferred Tax Assets, Charitable Contribution Carryforwards $5.80M.
- 2023-12-31: Deferred Tax Assets, Charitable Contribution Carryforwards $6.11M.
- 2022-12-31: Deferred Tax Assets, Charitable Contribution Carryforwards $4.78M.
| Period end | Deferred Tax Assets, Charitable Contribution Carryforwards |
|---|---|
| 2025-12-31 | $5.70M 10-K · filed 2026-02-19 |
| 2024-12-31 | $5.80M 10-K · filed 2026-02-19 |
| 2023-12-31 | $6.11M 10-K · filed 2025-02-21 |
| 2022-12-31 | $4.78M 10-K · filed 2024-02-20 |
| 2021-12-31 | $3.43M 10-K · filed 2023-02-23 |
| 2020-12-31 | $2.58M 10-K · filed 2022-02-24 |
| 2019-12-31 | $1.26M 10-K · filed 2021-03-01 |
| 2018-12-31 | $0.00 10-K · filed 2020-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| Dianthus Therapeutics, Inc. /DE/ (DNTH) | United States | $5.082B | -27.79 |
| Liquidia Corp (LQDA) | United States | $6.347B | 51.23 |
| Erasca, Inc. (ERAS) | United States | $5.073B | -19.96 |
| Veradermics, Inc (MANE) | United States | $4.839B |